Market Size and Growth
The Neuroscience Antibodies and Assays Market size was valued at US$ 5.19 billion in 2025 and is estimated to reach US$ 11.35 billion by 2033, growing at a CAGR of 5.39% during the forecast period (2026-2033).
Antibodies are used extensively in neuroscience research to help identify and elucidate reactions at the cellular, molecular, and biochemical levels, leading to a better understanding of various neuronal processes and diseases.
Market Scope
| Metrics | Details |
| Market CAGR | 5.39% |
| Segments Covered | By Product Type, By Technology, By End-User, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
To Get a Free Sample Click Here
Neuroscience Antibodies and Assays Market Dynamics
The factors expected to drive the global neuroscience antibodies and assays market are the increasing demand for antibodies and assays for neuroscience and a significant increase in the incidence of neurological diseases.
The increasing demand for antibodies and assays for neuroscience is expected to drive the market growth
The field of developmental neuroscience has a long and illustrious history. Recent advances in protein isolation and molecular biology have made it much easier to identify neural-specific developmental processes, allowing for significant progress in the field. As a result, novel neural proteins involved in the development and maturation of various systems make up a large portion of the new targets investigated thus far. For instance, Merck has a wide range of antibodies, kits, and assays to help with developmental neuroscience research.
Moreover, antibodies are used in neurobiology research for a variety of purposes. Each application helps researchers better understand the structure and function of specialised cells in the nervous system. Some of the applications are Western blotting detection, Immunohistochemistry, immunocytochemistry, and immunofluorescence to visualise live and fixed cells or tissues. Immunoprecipitation is used to enrich proteins and study protein interactions. Flow cytometry and FACS quantify, characterize, identify, and isolate cell types/populations. In neurobiology, antibodies investigate neuronal markers, cellular differentiation, and disease markers in the nervous system. In complex cellular systems like neurons, target-specific antibodies can aid in detecting low-abundance proteins.
Neuroscience Antibodies and Assays Segment Analysis
Immunoassays segment is expected to dominate the market growth in the forecast period
Immunoassays are chemical tests that use an antibody or an antigen to determine the presence or concentration of a macromolecule or a small molecule in a solution. Immunoassays are widely used in various settings, including disease diagnosis, therapeutic drug monitoring, and pharmacokinetic and bioequivalence studies in drug development. According to WHO, neurological disorders affect hundreds of millions worldwide, including more than 50 million people with epilepsy and around 47 million people with dementia.
Due to the development of novel antibodies, technological advancements in immunoassays, and increasing government initiatives in the genomics and proteomics research field, the segment holds a significant market share in the neuroscience antibodies and assays market, expected to show a similar trend over the forecast period. The immunoassays segment is being driven by the rising incidence of neurological diseases, technological advancements in immunoassays, and increased research and development activities.
Neuroscience Antibodies and Assays Market Geographical Analysis
North America region is expected to hold the largest market share in the global neuroscience antibodies and assays market
The rising incidence of neurological diseases, an increase in research and development activities, and growth in the pharmaceutical and biotechnology industries in this region are expected to drive the market growth.
According to Pan American Health Organization (PAHO), in 2019, neurological conditions accounted for the following there were 533,172 deaths, with 213,129 (40%) men and 320,043 (60%) women. 32.9 deaths per 100,000 people (age-standardized), with men suffering 33.1 deaths per 100,000 people and women suffering 32.2 deaths per 100,000 people. Alzheimer's disease and other dementias affect millions of people in the United States. As the number of people aged 65 and up in the United States grows, so will the number of people with Alzheimer's disease or other dementias. The number and proportion of Americans aged 65 and older are expected to rapidly increase in the coming years, rising from 56 million in 2020 to 88 million by 2050. In 2020, an estimated 5.8 million Americans aged 65 and up were diagnosed with Alzheimer's disease. Eighty percent of the population is 75 years old or older.
Neuroscience Antibodies and Assays Companies & Competitive Landscape
The global neuroscience antibodies and assays market is moderately competitive, with increasing mergers, acquisitions, and collaborations are expected to drive the market growth. Some of the key players in the market are Thermo Fisher Scientific, Bio-Rad Laboratories, Inc, Merck KGaA, F. Hoffmann-La Roche, Cell Signaling Technology, Inc, BioLegend, Inc, Abcam Plc, Rockland Immunochemicals, Inc, GenScript, Santa Cruz Biotechnology, Inc
Thermo Fisher Scientific
Overview: Thermo Fisher Scientific is scientific instrumentation, reagents and consumables, and software services company based in the United States. The company is based in Waltham, Massachusetts. The company was founded in 1956.
Product Portfolio: For neuroscience research, the company has a wide range of highly specific antibodies validated for various applications. Depending on the type of research, neurobiology antibodies cover a wide range of targets and markers.
Key Developments:
- February 2026: Industry reports highlighted ongoing growth drivers in the neuroscience antibodies and assays market, emphasizing advancements in biomarker therapies and neuroimmunology research collaborations.
- January 2026: Leading biotech firms in the USA expanded their portfolios of next-generation monoclonal antibodies targeting biomarkers for Alzheimer's and Parkinson's diseases, enhancing translational research pipelines.
- December 2025: Research institutions in Japan partnered with life science companies to develop high-sensitivity neuroinflammation assay kits aimed at early detection of CNS disorders.
Trending Topics 2026
